The firm said that molecular product sales were up 103 percent, driven by the launch of the Solana Group A Strep assay earlier this year.
The FDA has approved Merck's Keytruda as a first-line treatment for non-small cell lung cancer in patients with high PD-L1 expression.
The test enables donor screening laboratories to use PCR-based diagnostic technology to screen donated blood and plasma.
The test uses the helicase-dependent amplification technology that underpins Quidel's AmpliVue line of molecular assays.
The firm's multi-analyte quality controls for nucleic acid tests are designed to help large and small labs mitigate quality challenges.
The PCR-based assays run on the company's Aries system, which itself received FDA clearance in October 2015.
The M1, a lower-throughput version of the company's Aries System, can process up to six samples and six assays at a time.
It is the first FDA-approved test for the stem cell transplant use case and meets the WHO International Standard for comparable results.
The software connects Luminex's FDA-cleared Aries PCR-based platform with its multiplex xMap technology-based Magpix system.
With this clearance, the respiratory pathogen panel is ready to enter the market to aid in accurate patient diagnosis for respiratory illness.
In a cartoon, Vox explores the lack of women among this year's winners of the Nobel Prize.
Science reports a new US defense bill would establish two groups aimed at combating foreign influence on research.
Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.
In Cell this week: analysis of tissue clones, metagenomic studies of ocean water samples, and more.
